Data
Combination Therapy in Ovarian Cancer
Story | Cancer type | Organism | Modality | Link | Antibodies targets in the story |
---|---|---|---|---|---|
BRCA-WT TNBC 1 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA-WT TNBC 2 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA-WT TNBC 3 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA-WT TNBC 4 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA-WT TNBC 5 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA-WT TNBC 6 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 1 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 2 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 3 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 4 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 5 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 6 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 7 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 8 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 9 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
BRCA1-associated TNBC 10 | Breast | Human | CyCIF | Here | CD163, CD68, Keratin, Ki67, 53BP1, CD4, CD8a, FOXP3 |
Clinical Benefit - Cisplatin Biopsy | Breast | Human | CyCIF | Here | pCDK1/2/3/5, pHH3, pan-cytokeratin, CD8a, CD4, CD68, CD163, CD14 |
Clinical Benefit - Cis Wee1i Biopsy | Breast | Human | CyCIF | Here | pCDK1/2/3/5, pHH3, pan-cytokeratin, CD8a, CD4, CD68, CD163, CD14 |
No Clinical Benefit - Cisplatin Biopsy | Breast | Human | CyCIF | Here | pCDK1/2/3/5, pHH3, pan-cytokeratin, CD8a, CD4, CD68, CD163, CD14 |
No Clinical Benefit - Cis Wee1i Biopsy | Breast | Human | CyCIF | Here | pCDK1/2/3/5, pHH3, pan-cytokeratin, CD8a, CD4, CD68, CD163, CD14 |
Spatially resolved immune profiling of lung adenocarcinoma mouse model KRas/p53 mutant | Lung | GEMM | CyCIF | Here | TTF1, CD45, CD11c, CD45R, FOXP3, CD4, CD8, Granzyme B, Perforin |
Tonsil | Normal | Human | CyCIF | Here | CD45, IBA1, Keratin, α-SMA, CD20, CD3d, CD4, CD8a, CD14, CD163, CD11b, CD68 |
Tonsil | Normal | Human | IHC | Here | CD3, CD4, CD8, CD20, CD68, FOXP3, PD1, PD-L1 |
Lung-1-LN: Lung adenocarcinoma metastasis to lymph node | Lung | Human | CyCIF | Here | CD45, IBA1, Keratin, α-SMA, CD20, CD4, CD8a, CD163, CD11b, CD68, CD14, |
Lung-2-BR: Lung squamous cell carcinoma metastasis to brain | Lung | Human | CyCIF | Here | CD45, IBA1, Keratin, α-SMA, CD20, CD4, CD8a, CD163, CD11b, CD68, CD14, |
Lung-3-PR: Primary lung squamous cell carcinoma | Lung | Human | CyCIF | Here | Keratin, α-SMA, CD45, IBA1, PD-L1, CD3d, CD20, CD4, FOXP3, CD8a, PD1, LAG3, CD163, CD68, CD11b, CD14 |
TOPACIO Responder | Ovarian | Human | CyCIF | ||
TOPACIO Non-responder | Ovarian | Human | CyCIF |